Canaccord update on ITX22 Jan 2025 08:08
Strong cash performance to close 2024
Itaconix has this morning reported FY24 revenue of $6.5mn with gross profit margins increasing to approximately 35%, up from 31% in 2023, both in line with existing guidance and our forecasts. The company continues to see significant growth in cleaning, particularly in Europe, and notable revenue increases in hygiene and beauty due to higher volumes from Croda and Nouryon. Formulated Solutions continues to expand, with the SPARX program expected to introduce at least 10 new products in 2025.
We estimate that excluding the low-margin distributor sales, discontinued in early 2024, Itaconix's underlying revenue grew around 70% y/y, an impressive expansion.
End-2024 net cash was $6.7mn (CGe $6.2mn), due to better than expected working capital performance. We are updating our numbers for the better cash performance but making no other material changes; we continue to see substantial further growth into 2025E and for the group to become EBITDA positive in 2026E.
We remain BUYers with an unchanged 325p price target.